Pause at Your Own Peril: A Case Series on Rebound Pulmonary Hypertension.
interruption of therapy
pulmonary artery hypertension
rebound pulmonary arterial hypertension
restarting therapy
severe pulmonary arterial hypertension
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
30
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
Severe pulmonary arterial hypertension (PAH) is associated with high morbidity and mortality. Therapeutic approaches for intermediate- and high-risk pulmonary arterial hypertension have now shifted toward initial combination management, often including parenteral epoprostenol and iloprost and early assessment for a lung transplant. After the initiation of therapy, usually various combinations of different classes of medication, it is important to consider the potential interruption in therapy causing rebound PAH. We present two patients recently admitted to our hospital with rebound symptoms after interruption of their pulmonary vasodilator therapy.
Identifiants
pubmed: 35783883
doi: 10.7759/cureus.25552
pmc: PMC9249055
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e25552Informations de copyright
Copyright © 2022, Murali et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Anesthesiology. 2004 Apr;100(4):1023-5
pubmed: 15087645
Vasc Health Risk Manag. 2008;4(5):1111-3
pubmed: 19183760
J Cardiovasc Pharmacol Ther. 2020 Mar;25(2):131-141
pubmed: 31594400
Eur Respir J. 2015 Oct;46(4):903-75
pubmed: 26318161
Respir Med. 2015 May;109(5):557-64
pubmed: 25666253
Pulm Circ. 2017 Apr-Jun;7(2):439-447
pubmed: 28597752
Am J Respir Crit Care Med. 2013 Aug 1;188(3):365-9
pubmed: 23600433
Pulm Circ. 2018 Jan-Mar;8(1):2045893217753352
pubmed: 29283031